Latest news and press releases about Caris Life Sciences, Inc. (CAI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms.
Price
| Price | $30.39 |
| Market Cap | $8.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 76.10 |
| Price / Book | 13.53 |
| EV / EBITDA | 48.37 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 18.77% |
| Return on Invested Capital | 14.67% |
| Return on Assets | 8.55% |
| Gross Margin | 69.66% |
| Operating Margin | 15.49% |
| Net Margin | 10.62% |
Related companies: ABVX · CORT · CYTK · HALO · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of CAI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks